Generic placeholder image

Mini-Reviews in Medicinal Chemistry


ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Review Article

Nanotechnology as Potential Strategy for the Treatment of Pharmacoresistant Epilepsy and Comorbid Psychiatric Disorders

Author(s): Argelia Rosillo-de la Torre, Luisa Rocha, Hermelinda Salgado-Ceballos, Perla E. García Casillas and Gabriel Luna-Barcenas

Volume 17, Issue 3, 2017

Page: [237 - 246] Pages: 10

DOI: 10.2174/1389557516666161013105000

Price: $65


Background: Pharmacoresistant epilepsy is a disabling neuronal disorder with harmful consequences that impact patient’s quality of life. Although psychiatric comorbidities are frequently present in patients with epilepsy, they are more common in those patients with pharmacoresistant epilepsy. Despite medical advances, the current existing therapeutic strategies for pharmacoresistant seizure control are not available for all patients and/or present disadvantages. Moreover, the conventional drug therapies for psychiatric comorbidities have several adverse effects. Therefore, in this field, nanotechnology arises as a novel tool for transporting drugs to the brain under pathological conditions with high efficiency and low side effects.

Objective: Present an overview of nanotechnology as a novel, efficient and enhanced therapeutic strategy for controlling pharmacoresistant epilepsy and its associated psychiatric comorbidities.

Conclusion: Nanotechnology emerges as a powerful tool for the control and/or treatment of pharmacoresistant epilepsy and its comorbidities in a more efficient and safer way than conventional treatments.

Keywords: Nanotechnology, Pharmacorresistant epilepsy, Psychiatric comorbidity, Seizures, Side effects.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy